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on hourly labour costs is used for productivity costs per working day/hour.
RESULTS:Vacancy durations estimated in 2009 for The Netherlands, Belgium, Ger-
many, France, the UK, Norway and Sweden range between 40-80 days. Regression
analysis of the vacancy durations shows that, there is a strong negative relation-
ship between vacancy durations and unemployment rates. When unemployment
increases, vacancy durations and hence friction period decline. We also find that
an increase in the vacancy rate (the ratio of the stock of vacancies to total labor
force) has a positive effect on vacancy durations which can be explained by the
congestion provoked by the increase in the number of vacancies competing in the
labor market.CONCLUSIONS:This paper provides estimates on vacancy durations,
friction periods and the price component in order to calculate the friction costs. For
seven European countries, we present empirical estimates to use the friction cost
method in a practical way which can improve more uniform analysis of productiv-
ity costs in economic evaluations of diseases. Our regression results confirm the
validity of estimated vacancy durations which are necessary to calculate the length
of friction period and friction costs.
PC3
BREAST AND PROSTATE CANCER PRODUCTIVITY COSTS: A COMPARISON OF
THE HUMAN CAPITAL APPROACH AND FRICTION COST APPROACH
Hanly P, Timmons A, Walsh P, Sharp L
National Cancer Registry Ireland, Cork, Ireland
OBJECTIVES: Productivity costs constitute a substantial proportion of the total
societal costs associated with cancer. Cancer patients may leave the workforce
permanently post-diagnosis, take time off during treatment and/or return to work
with reduced hours or die prematurely; the associated productivity costs have
rarely been considered. We applied the dominant human capital approach (HCA)
and the emerging friction cost approach (FCA) to estimate breast and prostate
cancer productivity costs in Ireland in 2008. METHODS: Data from a survey of
breast and prostate cancer patients (n358) was combined with population-level
survival estimates (from the population-based National Cancer Registry) and a
national wage dataset to calculate costs of temporary disability (cancer-related
work absence), permanent disability (workforce departure, reduced working hours)
and premature mortality, using the HCA and FCA. Sensitivity analyses were con-
ducted for key parameters: GNP growth and discount rates for HCA and friction
period and labour elasticity for FCA. RESULTS: According to the HCA, productivity
costs per person amounted to €193,425 for breast and €109,154 for prostate cancer.
FCA per person costs were €8103 for breast and €8205 for prostate cancer. The HCA
generated higher costs for younger patients (breast cancer) due to greater lifetime
earning potential. In contrast FCA resulted in higher productivity costs for older
male patients (prostate) commensurate with higher earning capacity over a shorter
time period. Reduced working hours post-cancer was a key driver of total HCA
productivity costs. HCA costs were sensitive to assumptions about discount and
growth rates. FCA costs were sensitive to assumptions about the friction period.
CONCLUSIONS: This study highlights the importance of choosing the correct val-
uation method for chronic long-term illnesses such as cancer, being explicit about
assumptions, and considering a range of cost sub-components, including those
due to reduced working hours.
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OBJECTIVES: The aim of this study was to estimate the impact of pandemic
Influenza A H1N1/2009 in terms of patient’s health care services utilization,
work absenteeism and associated costs. METHODS: Longitudinal, descriptive,
multi-centre study of in- and outpatients with confirmed diagnosis of influenza A
H1N1/2009 in Spain. Sociodemographic and clinical characteristics were gathered
together with health and social resources use, at the admission or primary visit,
and also after recovery. Cost analyses were conducted under a social perspective,
incidence focus and with a temporal horizon of 3 months. Unit cost of resources
was imputed to calculate the mean cost by inpatient and outpatient. A sensitivity
analysis with variations was conducted (Monte Carlo simulation). RESULTS:A total
of 172 inpatients and 224 outpatients were included, 20% and 30% of whom, re-
spectively, were under 17 years old; 12% of inpatients were at ICU, 7.8 (SD3.7)
days, on average, and stayed in general wards for 9.6 (SD7.7) additional days. The
rest of inpatients had a mean hospitalization length of 5 (SD4.4) days. The most
frequently used ambulatory health resource was the primary care medical assis-
tance; 43.8% of inpatients and 66.1% of outpatients were employed, of whom 100%
(inpatients) and 91.7% (outpatients) went on sick leave. Absenteeism length was of
30 (SD20.7) days for inpatients and 9 (SD6.3) for outpatients. Caregivers of 21.7%
of the inpatients also led work absenteeism, as well as the 8.5% of those of outpa-
tients. The proportion of indirect cost for general-ward-inpatients was 30%. This
percentage ascended to 77% in the case of outpatients. The mean costs per inpa-
tient were €6,236 (CI95%1,384–14,623) and €940 (CI95%66–3,064) per outpatient.
CONCLUSIONS: Hospitalizations represents the highest economic cost, together
with work absenteeism. Since only a marginal proportion of influenza cases are
hospitalized, productivity losses emerge as the most important impact of the dis-
ease.
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OBJECTIVES: This study evaluated several recent drug launches in Rheumatoid
Arthritis (RA) to determine which factors contribute to Health Technology Ap-
praisal (HTA) outcomes. METHODS: We reviewed the appraisals of RA drugs
launched in the last five years by the following HTA agencies: England (NICE),
Scotland (SMC), Sweden (TLV), France (HAS), Spain (CAHTA/CANM) and The Neth-
erlands (CVZ). We analysed the proportion of recommended, restricted and not
recommended appraisals and the reasons for these decisions. A subsequent anal-
ysis of the evidence and arguments developed in the appraisal by the HTA agency
was performed. We classified them as clinical, economic, humanistic or social, in
addition we analysed the outcome by country and drug. RESULTS: The listed HTA
agencies issued a total of 25 appraisals (first appraisal, indication expansion and
re-appraisal) for the 4 drugs analysed (certolizumab, golimumab, tocilizumab and
abatacept). There were 9 recommendations for use (36%), 13 restricted use deci-
sions (52%) and 3 decisions to not recommend for use (12%). In 96% of the cases, the
study design (population, add-on vs. monotherapy, duration of trials, comparators
etc.) were systematically quoted as the primary reason for the HTA agency deci-
sion. In 44% of these cases, in addition to design issues, the lack of convincing
health economic data was mentioned. The reasons for favourable recommenda-
tions were 100% clinical and 56% economic, for restricted 100% clinical and 31%
economic and in case of non-recommendation 67% clinical and 67% economic.
CONCLUSIONS: The primary reason for restriction and non-recommendation are
clinical design issues. Consequently it is recommended that manufacturers incor-
porate payer’s expectations in their development plan early enough to influence
trial design and to collect robust health economic evidence.
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OBJECTIVES: The recent UK value-based pricing (VBP) consultation proposes that
burden of illness, therapeutic improvement/innovation and wider societal benefits
are evaluated in addition to cost-effectiveness. This study explored attitudes
among industry, academia and UK National Health Service (NHS) stakeholders to
the proposed VBP framework, with a focus on how to define the burden of illness
component. METHODS: Relevant literature was identified via a manual search to
assess the use of VBP methodologies in other countries and potential burden of
illness (BOI) criteria. In-depth, semi-structured 40-minute telephone interviews
were then undertaken with 20 experts identified in UK academic centres, the phar-
maceutical industry and the NHS. Discussions explored perspectives on VBP and in
particular how to define and evaluate BOI. RESULTS: Proposed definitions for BOI
varied significantly. Industry representatives wanted the flexibility to use a broad,
variable set of criteria, while academic and NHS stakeholders wanted practical,
consistent evaluation criteria with the emphasis on ensuring benefits are not ‘dou-
ble-counted’. Stakeholder input was used to develop a framework for assessing BOI
comprising disease severity, quality of life impact, treatment availability and per-
formance of existing treatments. Qualitative grading scales for each of the criteria
were proposed. While each stakeholder group broadly endorsed VBP objectives, the
research highlighted various concerns regarding its implications. In particular, the
need for clear government policy and guidance, further development of acceptable
evaluation methodologies (including criteria weightings), and enhanced pharma-
ceutical development processes to ensure evidence of sufficient quality is gener-
ated to support evaluation of product value (both at launch and over time).
CONCLUSIONS: There appears to be sufficient common ground to develop a BOI
assessment framework that is acceptable to both industry and NHS stakeholders.
We propose a relatively simple model that could form the basis for further research
and discussion, with special attention to addressing the implementation chal-
lenges.
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OBJECTIVES: The Pharmaceutical Market Restructuring Act (AMNOG) came into
action in Germany January 2011 with the aim of containing rising health care
expenditure, notably by introducing mandatory benefit assessments and price ne-
gotiation for all new innovative pharmaceuticals. The impact of the reform for the
pharmaceutical industry is predicted to be at its highest with repercussions beyond
the country’s borders, due to Germany’s strategic importance in the European
market. This project aimed to identify the challenges and opportunities created for
the industry in terms of pricing and market access of innovative pharmaceuticals.
METHODS: The impact was measured from three angles by developing hypotheses
and testing them thanks to a series of exploratory interviews with pharmaceutical
companies and Market access stakeholders. RESULTS: Results obtained project
that the impact of the reform for the industry will be very high, increasing the
importance of national stakeholders, altering the cost, time and strategy for mar-
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